NZ595294A - Intraocular sustained release drug delivery systems and methods for treating ocular conditions - Google Patents

Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Info

Publication number
NZ595294A
NZ595294A NZ595294A NZ59529410A NZ595294A NZ 595294 A NZ595294 A NZ 595294A NZ 595294 A NZ595294 A NZ 595294A NZ 59529410 A NZ59529410 A NZ 59529410A NZ 595294 A NZ595294 A NZ 595294A
Authority
NZ
New Zealand
Prior art keywords
sustained release
methods
drug delivery
delivery systems
microspheres
Prior art date
Application number
NZ595294A
Other languages
English (en)
Inventor
James A Burke
Werhner C Orilla
Hui Liu
Marianne M Do
Scott Whitcup
Patrick M Hughes
Alazar N Ghebremeskel
Kun Xu
Lon T Spada
Michael R Robinson
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NZ595294A publication Critical patent/NZ595294A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ595294A 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions NZ595294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/411,250 US20100247606A1 (en) 2009-03-25 2009-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions
PCT/US2010/028584 WO2010111449A1 (en) 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Publications (1)

Publication Number Publication Date
NZ595294A true NZ595294A (en) 2013-11-29

Family

ID=42326990

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595294A NZ595294A (en) 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Country Status (13)

Country Link
US (1) US20100247606A1 (enExample)
EP (1) EP2411013B1 (enExample)
JP (2) JP2012521997A (enExample)
KR (4) KR20170064556A (enExample)
CN (1) CN102497865A (enExample)
AU (3) AU2010229891A1 (enExample)
BR (1) BRPI1012324A2 (enExample)
CA (1) CA2756065A1 (enExample)
IL (1) IL215205A0 (enExample)
MX (1) MX2011009901A (enExample)
NZ (1) NZ595294A (enExample)
RU (2) RU2532333C2 (enExample)
WO (1) WO2010111449A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2762536C (en) 2009-05-18 2019-05-21 Dose Medical Corporation Drug eluting ocular implant
KR20180117211A (ko) 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
CA2794956C (en) 2010-04-03 2017-05-02 Praful Doshi Medical devices including medicaments and methods of making and using same
US20120022137A1 (en) * 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
RU2013111281A (ru) * 2010-08-17 2014-09-27 Аллерган, Инк. Агонисты ер2 или ер4 для лечения помутнения роговицы
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US8715713B2 (en) 2011-04-29 2014-05-06 Allergan, Inc. Solvent cast film sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP2570402A1 (en) * 2011-09-16 2013-03-20 Fovea Pharmaceuticals Bi-aryl derivatives, their preparation and their therapeutic application
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
WO2013037705A2 (en) * 2011-09-16 2013-03-21 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
CN104055695B (zh) * 2013-03-22 2016-12-28 深圳市绿蛙生物科技有限公司 中药型快干消毒护手霜及其制备方法
RU2015146211A (ru) * 2013-04-01 2017-05-19 Аллерган, Инк. Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения
JP2016520561A (ja) * 2013-04-12 2016-07-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 脂肪減少のためのビマトプロスト、ビマトプロスト類似体、プロスタミド及びプロスタグランジンの持続放出
SG11201603383VA (en) 2013-10-31 2016-05-30 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
WO2015085251A1 (en) * 2013-12-06 2015-06-11 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2015175544A1 (en) * 2014-05-12 2015-11-19 Allergan, Inc. Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN105266952A (zh) * 2014-07-09 2016-01-27 首都医科大学附属北京同仁医院 一种抗青光眼手术中所用防术后结膜粘连的器材
JP7026507B2 (ja) * 2014-09-06 2022-02-28 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
MX393691B (es) * 2015-06-06 2025-03-24 Cloudbreak Therapeutics Llc Composiciones y metodos para tratar pterigion.
JP6914931B2 (ja) * 2015-07-23 2021-08-04 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017062770A1 (en) 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US12171869B2 (en) * 2016-09-23 2024-12-24 Incept, Llc Intracameral drug delivery depots
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
RU2685499C1 (ru) * 2018-07-19 2019-04-18 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения прогрессирующей миопии у детей с выявленным привычно-избыточным напряжением аккомодации
US20200069696A1 (en) * 2018-08-30 2020-03-05 Yunxiang Liu Ophthalmic injectable formulation preparing and oculopathy treating and preventing
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
KR20210139250A (ko) * 2019-02-08 2021-11-22 오하이오 스테이트 이노베이션 파운데이션 항산화제-방출 유리체 대체물 및 이의 용도
IL295357B1 (en) 2020-02-06 2025-12-01 Ocular Therapeutix Inc Travoprost sustained-release biodegradable intracameral implants for use in the treatment of ocular diseases
TW202202138A (zh) 2020-03-25 2022-01-16 美商歐克萊製藥公司 含有酪胺酸激酶抑制劑之眼用植入物
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
EP4149400A4 (en) * 2020-05-15 2024-05-01 Georgia Tech Research Corporation METHODS AND COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE
WO2021247690A1 (en) * 2020-06-03 2021-12-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
CA3206609A1 (en) * 2021-02-05 2022-08-11 Weizhen Wang Compositions and methods for periorbital administration of ep2 receptor agonists
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
AU2024275112A1 (en) * 2023-05-19 2026-01-15 The Trustees Of Columbia University In The City Of New York Treating elevated intraocular pressure with nicotinamide

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT252264B (de) * 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3749776A (en) * 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US4403353A (en) * 1981-06-25 1983-09-13 Tennant Jerald L Anterior chamber implant lens
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
DE60325511D1 (de) * 2002-11-06 2009-02-05 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
CA2553381C (en) * 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
EP1718274A2 (en) * 2004-01-26 2006-11-08 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
CN101137622A (zh) * 2005-03-10 2008-03-05 阿勒根公司 作为治疗剂的取代的γ内酰胺
MX339797B (es) * 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
BRPI0619966A2 (pt) * 2005-12-16 2011-10-25 Alcon Inc controle de pressão intra-ocular usando agentes de modulação de alk5
JP5388582B2 (ja) * 2006-01-17 2014-01-15 トランセンド・メディカル・インコーポレイテッド 薬剤投与処置装置
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
MX2009001334A (es) * 2006-08-07 2009-02-13 Bausch & Lomb Tratamiento de infecciones y secuelas de las mismas con agonistas de receptor de glucocorticoide disociado y agentes anti-infecciosos, combinados.
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8722726B2 (en) * 2007-01-25 2014-05-13 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
EP2217581B1 (en) * 2007-11-09 2013-07-31 Allergan, Inc. Substituted cyclopentanes having prostaglandine activity
CA2721749A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
KR20180117211A (ko) * 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물

Also Published As

Publication number Publication date
KR20160120800A (ko) 2016-10-18
RU2664686C2 (ru) 2018-08-21
US20100247606A1 (en) 2010-09-30
AU2016231616A1 (en) 2016-10-20
WO2010111449A1 (en) 2010-09-30
RU2532333C2 (ru) 2014-11-10
EP2411013A1 (en) 2012-02-01
KR20180108883A (ko) 2018-10-04
BRPI1012324A2 (pt) 2016-03-15
CA2756065A1 (en) 2010-09-30
CN102497865A (zh) 2012-06-13
JP2012521997A (ja) 2012-09-20
EP2411013B1 (en) 2020-08-19
MX2011009901A (es) 2011-11-18
AU2010229891A1 (en) 2011-10-20
AU2018211329A1 (en) 2018-08-23
JP2015007117A (ja) 2015-01-15
IL215205A0 (en) 2011-12-29
KR20120006998A (ko) 2012-01-19
KR20170064556A (ko) 2017-06-09
RU2014133501A (ru) 2016-03-10
RU2011140433A (ru) 2013-04-27

Similar Documents

Publication Publication Date Title
NZ595294A (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
Wenk et al. Silk fibroin as a vehicle for drug delivery applications
JP2012521997A5 (enExample)
NZ619297A (en) Intraocular drug delivery systems
EP1962798B1 (en) Injectable formulation capable of forming a drug-releasing device
WO2008157614A3 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
EP1933881B1 (en) Solid polymer delivery compositions and methods for use thereof
JP6282231B2 (ja) 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
JP2018500394A5 (enExample)
JP2010511433A5 (enExample)
WO2010062523A3 (en) Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
JP2008540552A5 (enExample)
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
JP2013523821A5 (enExample)
JP2014156496A5 (ja) 生分解性眼内インプラント
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
WO2010005721A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
BR112013013123A2 (pt) dispositivo de entrega de fármaco
EP1786400A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES
JP2009535422A5 (enExample)
WO2011112996A3 (en) Injectable drug delivery system
US20140296449A1 (en) Methods for preparing polymers having low residual monomer content
JP2011508791A5 (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2023 BY THOMSON REUTERS

Effective date: 20220302

LAPS Patent lapsed